|Description||Neurostimulation device for OSA|
|VENTURE FUNDING TOTAL||$4M|
|Venture Round, 10/11 |
Through targeted tongue-muscle neurostimulation, ImTheraâ€™s open-loop multi-contact device (aura6000â„¢) based on its proprietary THN Sleep Therapyâ„¢ stimulates key tongue muscles during sleep, opening the upper airway and substantially reducing or eliminating OSA events.
An estimated 38 million Americans have OSA and while CPAP is the established therapy, studies show that only 46 percent of patients comply with wearing CPAP masks.
Our mission is to help patients live longer and enjoy better lives while substantially reducing health care costs related to serious complications associated with Obstructive Sleep Apnea.